GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Chi Sheng Pharma & Biotech Co 4111.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

28.45

+0.89%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 1.38bn

FY2016FY2025

Net income

TWD 164.3m

FY2016FY2025

Free cash flow

TWD 180.1m

FY2016FY2025

Shareholders' equity

TWD 1.38bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 1.38bnTWD 1.17bnTWD 1.06bnTWD 1.14bnTWD 1.02bnTWD 979.4mTWD 1.02bnTWD 967.4mTWD 1.04bnTWD 963.7m
Gross profitTWD 543.7mTWD 397.2mTWD 343.1mTWD 422.5mTWD 356.6mTWD 322.9mTWD 340.2mTWD 369.4mTWD 345.7mTWD 306.8m
Research and developmentTWD 16.5mTWD 18.0mTWD 21.7mTWD 19.7mTWD 18.9mTWD 18.2mTWD 20.6mTWD 22.5mTWD 23.0mTWD 18.8m
Operating incomeTWD 199.3mTWD 98.9mTWD 61.2mTWD 163.8mTWD 132.9mTWD 81.6mTWD 97.5mTWD 42.6mTWD 103.3mTWD 81.3m
Net incomeTWD 164.3mTWD 110.6mTWD 68.7mTWD 154.0mTWD 80.8mTWD 59.1mTWD 72.5mTWD 42.3mTWD 81.7mTWD 72.8m
Diluted earnings per share2.871.931.192.701.421.041.270.741.431.21

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 1.94bnTWD 1.75bnTWD 1.77bnTWD 1.80bnTWD 1.66bnTWD 1.49bnTWD 1.52bnTWD 1.50bnTWD 1.48bnTWD 1.43bn
Cash and short-term investments———TWD 456.3mTWD 252.3mTWD 335.8mTWD 275.2m——TWD 118.6m
Total liabilitiesTWD 557.0mTWD 475.1mTWD 547.0mTWD 578.4mTWD 559.0mTWD 410.9mTWD 450.3mTWD 458.2mTWD 428.4mTWD 413.4m
Debt———TWD 290.4mTWD 292.2mTWD 148.6mTWD 172.8m———
Shareholders' equityTWD 1.38bnTWD 1.27bnTWD 1.22bnTWD 1.22bnTWD 1.10bnTWD 1.08bnTWD 1.07bnTWD 1.05bnTWD 1.05bnTWD 1.02bn
Shares outstanding57m57m57m57m57m57m57m57m57m60m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsTWD 274.6mTWD 213.2mTWD 74.5mTWD 214.9mTWD 139.3mTWD 143.5mTWD 163.0mTWD 114.2mTWD 181.1mTWD 103.7m
Capital spending−TWD 94.5m−TWD 85.2m−TWD 102.0m−TWD 105.9m−TWD 265.5m−TWD 22.8m−TWD 36.9m−TWD 75.4m−TWD 46.8m−TWD 73.7m
Free cash flowTWD 180.1mTWD 128.0m−TWD 27.5mTWD 109.0m−TWD 126.2mTWD 120.7mTWD 126.1mTWD 38.8mTWD 134.3mTWD 30.0m
Dividends paid−TWD 57.0m−TWD 57.0m−TWD 68.4m−TWD 57.0m−TWD 57.0m−TWD 57.0m−TWD 34.2m−TWD 45.6m−TWD 45.6m−TWD 34.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 375.1mTWD 356.8mTWD 347.0mTWD 342.1mTWD 367.8mTWD 319.6mTWD 331.5mTWD 284.3m
Gross profitTWD 141.8mTWD 146.2mTWD 139.3mTWD 132.4mTWD 150.3mTWD 121.7mTWD 126.0mTWD 98.2m
Operating incomeTWD 51.9mTWD 57.8mTWD 51.5mTWD 42.9mTWD 61.7mTWD 43.3mTWD 45.4mTWD 25.4m
Net incomeTWD 44.4mTWD 53.9mTWD 45.7mTWD 45.1mTWD 34.7mTWD 38.8mTWD 46.7mTWD 20.2m
Diluted earnings per share0.780.940.800.790.610.680.820.35
Cash from operationsTWD 87.0mTWD 3.0mTWD 96.0mTWD 119.0mTWD 17.0mTWD 41.0mTWD 66.0mTWD 20.0m
Capital spending−TWD 32.0m−TWD 25.0m−TWD 14.0m−TWD 14.0m−TWD 11.0m−TWD 53.0m−TWD 16.0m−TWD 22.0m
Free cash flowTWD 55.0m−TWD 22.0mTWD 82.0mTWD 105.0mTWD 6.0m−TWD 12.0mTWD 50.0m−TWD 2.0m
Total assetsTWD 2.04bnTWD 1.95bnTWD 1.94bnTWD 1.91bnTWD 1.84bnTWD 1.78bnTWD 1.75bnTWD 1.71bn
Shareholders' equityTWD 1.40bnTWD 1.43bnTWD 1.38bnTWD 1.34bnTWD 1.29bnTWD 1.31bnTWD 1.27bnTWD 1.23bn

Financial ratios

Data as of 31 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin39.5%34.1%32.3%37.0%34.9%33.0%—
Operating margin15.1%12.0%8.4%14.3%13.0%8.3%—
Net margin11.9%9.5%6.5%13.5%7.9%6.0%—
Return on equity11.9%8.7%5.6%12.6%7.3%5.5%—
Return on assets8.5%6.3%3.9%8.6%4.9%4.0%—
Free cash flow yield—18.3%10.8%19.7%24.9%10.2%—
Revenue growth18.1%9.9%-7.2%11.8%4.4%-4.3%—
Earnings growth48.5%61.1%-55.4%90.7%36.5%-18.4%—
Current ratio2.01x2.10x1.78x1.78x1.46x2.34x—
Debt to equity———0.24x0.26x0.13x0.15x
Equity ratio71.3%72.8%69.0%67.9%66.3%72.4%—
Interest coverage401.01x80.00x60.82x107.41x121.57x503.68x—
R&D as a share of sales1.2%1.5%2.0%1.7%1.9%1.9%—
Buybacks as a share of market value—0.4%-0.8%-0.1%0.0%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue6.4%7.0%4.0%
Operating income6.8%19.6%15.0%
Net income2.2%22.7%15.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin37.0%36.0%35.4%34.5%
Operating margin11.7%11.0%10.9%9.5%
Net margin10.8%10.5%9.4%8.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings10.313.721.29.615.522.018.731.016.217.5
Price to sales1.21.31.41.31.21.31.31.41.31.3

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 26 Aug 2025.

FY2025FY2024FY2023FY2022
Paid in the year1.000.9521.1430.952
  • 1050-for-1000 split · 26 Aug 2025
  • 1050-for-1000 split · 25 Aug 2025
  • 1040-for-1000 split · 17 Sept 2015
  • 1050-for-1000 split · 28 Aug 2014
  • 1.04-for-1 split · 4 Sept 2013
  • 1.02-for-1 split · 1 Sept 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.